NanOlogy
  • Home
  • About
  • Technology
    • Overview
    • Purcision Technology
  • Development
    • Investigational Drugs
    • Pipeline
    • Clinical Trials
    • Partnering Opportunities
  • News & Publications
  • Contact Us
    • Partnering Opportunities
    • Physicians and Patients
Post placeholder image
December 17, 2020 in Presentations

SABCS 2020 Poster: Phase 1/2 Clinical Trial of A Topical Submicron Particle Paclitaxel (SOR007) for the Treatment of Cutaneous Metastases

NanOlogy 0 Like Post Comments Off on SABCS 2020 Poster: Phase 1/2 Clinical Trial of A Topical Submicron Particle Paclitaxel (SOR007) for the Treatment of Cutaneous Metastases
Read More
NanOlogy

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.    Purcision is a trademark to CritiTech, Inc.  © NanOlogy LLC      Legal